Page 151 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GETCC
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
• Enhanced bioprocess control to advance the manufacture of mesenchymal stromal
cell-derived extracellular vesicles in stirred-tank bioreactors.
Biotechnol Bioeng. 2023;120(9):2725-41. doi: 10.1002/bit.28378.
Costa MHG, Costa MS, Painho B, Sousa CD, Carrondo I, Andreu-Oltra E, Pelacho B, Prós-
per F, Isidro IA, Alves P, Serra M.
• Therapeutic effect of adipose-derived mesenchymal stem cells in a porcine model
of abdominal sepsis.
Stem Cell Res Ther. 2023;14(1):365. doi: 10.1186/s13287-023-03588-x.
Vélez-Pinto JF, García-Arranz M, García-Bernal D, García Gómez-Heras S, Villarejo-Cam-
pos P, García-Hernández AM, Vega-Clemente L, Jiménez-Galanes S, Guadalajara H, Mo-
raleda JM, García-Olmo D. Grupo cooperativo coautor: Ricors-TERAV
• ZAKα/P38 kinase signaling pathway regulates hematopoiesis by activating the
NLRP1 inflammasome.
EMBO Mol Med. 2023;15(10):e18142. doi: 10.15252/emmm.202318142.
Rodríguez-Ruiz L, Lozano-Gil JM, Naranjo-Sánchez E, Martínez-Balsalobre E, Martínez-
López A, Lachaud C, Blanquer M, Phung TK, García-Moreno D, Cayuela ML, Tyrkalska SD,
Pérez-Oliva AB, Mulero V.
• Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early
predictive factors in patients with B-cell malignancies.
Front Immunol. 2023;14:1152498. doi: 10.3389/fimmu.2023.1152498.
García-Calderón CB, Sierro-Martínez B, García-Guerrero E, Sanoja-Flores L, Muñoz-Gar-
cía R, Ruiz-Maldonado V, Jimenez-Leon MR, Delgado-Serrano J, Molinos-Quintana Á,
Guijarro-Albaladejo B, Carrasco-Brocal I, Lucena JM, García-Lozano JR, Blázquez-Goñi C,
Reguera-Ortega JL, González-Escribano MF, Reinoso-Segura M, Briones J, Pérez-Simón
JA, Caballero-Velázquez T. Grupo cooperativo coautor: Hospital de la Santa Creu i Sant
Pau, Barcelona.
• Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation
in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised,
open-label, standard-of-care controlled, multicentre trial.
Lancet Neurol. 2023;22(2):137-46. doi: 10.1016/S1474-4422(22)00526-9.
Moniche F, Cabezas-Rodríguez JA, Valverde R, Escudero-Martínez I, Lebrato-Hernán-
dez L, Pardo-Galiana B, Ainz L, Medina-Rodríguez M, de la Torre J, Escamilla-Gómez
V, Ortega-Quintanilla J, Zapata-Arriaza E, de Albóniga-Chindurza A, Mancha F, Gamero
MA, Pérez S, Espinosa-Rosso R, Forero-Díaz L, Moya M, Piñero P, Calderón-Cabrera C,
Nogueras S, Jiménez R, Martín V, Delgado F, Ochoa-Sepúlveda JJ, Quijano B, Mata R,
151